142 related articles for article (PubMed ID: 37372998)
21. Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.
Kim SH; Kim JM; Shin MH; Kim CW; Huang SM; Kang DW; Suh KS; Yi ES; Kim KH
Histol Histopathol; 2012 May; 27(5):581-91. PubMed ID: 22419022
[TBL] [Abstract][Full Text] [Related]
22. Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer.
Zhu X; Guo Y; Li X; Ding Y; Chen L
J Thorac Oncol; 2010 Aug; 5(8):1159-66. PubMed ID: 20661085
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of 17-beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer.
Drzewiecka H; Gałęcki B; Jarmołowska-Jurczyszyn D; Kluk A; Dyszkiewicz W; Jagodziński PP
Lung Cancer; 2015 Feb; 87(2):107-16. PubMed ID: 25564397
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.
Zhou CH; Ye LP; Ye SX; Li Y; Zhang XY; Xu XY; Gong LY
J Exp Clin Cancer Res; 2012 Mar; 31(1):18. PubMed ID: 22385677
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail.
Choudhary R; Li H; Winn RA; Sorenson AL; Weiser-Evans MC; Nemenoff RA
Neoplasia; 2010 Mar; 12(3):224-34. PubMed ID: 20234816
[TBL] [Abstract][Full Text] [Related]
26. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis.
Pang L; Cheng Y; Zou S; Song J
Thorac Cancer; 2020 Feb; 11(2):264-276. PubMed ID: 31793741
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-7 inhibits the malignant phenotypes of non‑small cell lung cancer in vitro by targeting Pax6.
Luo J; Li H; Zhang C
Mol Med Rep; 2015 Oct; 12(4):5443-8. PubMed ID: 26135959
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-183 Acts as a Tumor Suppressor in Human Non-Small Cell Lung Cancer by Down-Regulating MTA1.
Yang CL; Zheng XL; Ye K; Ge H; Sun YN; Lu YF; Fan QX
Cell Physiol Biochem; 2018; 46(1):93-106. PubMed ID: 29587281
[TBL] [Abstract][Full Text] [Related]
31. Influence of miR-7a and miR-24-3p on the SOX18 transcript in lung adenocarcinoma.
Olbromski M; Rzechonek A; Grzegrzolka J; Glatzel-Plucinska N; Chachaj A; Werynska B; Podhorska-Okolow M; Dziegiel P
Oncol Rep; 2018 Jan; 39(1):201-208. PubMed ID: 29115529
[TBL] [Abstract][Full Text] [Related]
32. RNA-seq analysis reveals candidate genes associated with proliferation, invasion, and migration in BCL11A knockdown B-NHL cell lines.
Yin J; Xie X; Quan Y; Wang Z; Liu S; Su Q; Che F; Wang L
Ann Hematol; 2023 Jul; 102(7):1845-1856. PubMed ID: 37148312
[TBL] [Abstract][Full Text] [Related]
33. Differential expression and subcellular localization of Prohibitin 1 are related to tumorigenesis and progression of non-small cell lung cancer.
Jiang P; Xiang Y; Wang YJ; Li SM; Wang Y; Hua HR; Yu GY; Zhang Y; Lee WH; Zhang Y
Int J Clin Exp Pathol; 2013; 6(10):2092-101. PubMed ID: 24133587
[TBL] [Abstract][Full Text] [Related]
34. [Nuclear factor-kappaB activity and its correlation with cell proliferation in non-small cell lung cancer tissues].
Zhang J; Xu YJ; Zhang ZX; DU CL; Qiao LF; Ni W; Chen SX
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Oct; 30(10):771-5. PubMed ID: 18218209
[TBL] [Abstract][Full Text] [Related]
35. FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells.
Yang T; Li H; Thakur A; Chen T; Xue J; Li D; Chen M
Tumour Biol; 2015 Sep; 36(10):8185-91. PubMed ID: 25994569
[TBL] [Abstract][Full Text] [Related]
36. Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma.
Shikada Y; Yoshino I; Okamoto T; Fukuyama S; Kameyama T; Maehara Y
Clin Cancer Res; 2003 Nov; 9(14):5282-6. PubMed ID: 14614010
[TBL] [Abstract][Full Text] [Related]
37.
Jin Q; Chen Y; Du S; Xu D; Yue J; Cai L; Yuan X
Curr Cancer Drug Targets; 2022; 22(11):919-930. PubMed ID: 35909289
[TBL] [Abstract][Full Text] [Related]
38. [Expression of carbonic anhydrase IX in NSCLC and its relationship with VEGF and Ki67 expression].
Zhao X; Liu X; Guo W; Li X
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):861-6. PubMed ID: 20840814
[TBL] [Abstract][Full Text] [Related]
39. CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation.
Zhao Z; Li J; Jiang Y; Xu W; Li X; Jing W
Med Sci Monit; 2017 Jun; 23():2906-2916. PubMed ID: 28614291
[TBL] [Abstract][Full Text] [Related]
40. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
